Document Detail


Breast cancer during pregnancy: maternal and fetal outcomes.
MedLine Citation:
PMID:  20164696     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Breast cancer is the most common malignancy occurring during pregnancy. Because more women delay childbearing, the diagnosis of cancer during pregnancy will likely increase. Case reports exist in the literature regarding the treatment of pregnant women with breast cancer, but few are prospective and few provide long-term follow-up on the neonate exposed to chemotherapy. In this report, 130 women diagnosed with breast cancer were reported to our voluntary national registry and followed up prospectively. PATIENT AND METHODS: The Cancer and Pregnancy Registry is a voluntary registry that monitors the clinical course, treatment, and disease outcome of women diagnosed with cancer during pregnancy and the perinatal and neonatal outcomes of their children. RESULTS: Of the 130 diagnosed, 120 were diagnosed with a primary tumor, 8 with a recurrence, and 2 with a new primary cancer. Mean maternal age at diagnosis was 34.8 +/- 4.2 years. Mean gestational age at diagnosis was 13.2 +/- 8.1 weeks. Gestational age was 12.8 +/- 7.8 weeks for patients with primary disease and 16.25 +/- 11 weeks for those with recurrent cancer. One hundred thirteen women were followed up for mean of 3.14 +/- 2.5 years. Of those followed up, 103 were diagnosed with primary breast cancer during pregnancy, 8 with a recurrence, and 2 with a new primary. Recurrence was reported in 30 patients at an average of 16.2 +/- 10.8 months from delivery to recurrence. Twenty-one patients are deceased with an average of 24.71 +/- 15.32 months from delivery to death. Only 42% were diagnosed with an estrogen-positive tumor and 35% of cases had a progesterone receptor-positive tumor. Human epidermal growth factor receptor 2 was positive in 25% of patients. Chemotherapy was given during pregnancy in 104 cases; the first treatment was given at a mean gestational age of 20.4 +/- 5.4 weeks. The malformation rate of exposed neonates was 3 not greater than the general population. Survival by stage for a primary diagnosis in pregnancy is as follows: stage I, 100%; stage II, 86%; stage III, 86%; and stage IV, 0%. DISCUSSION: Pregnant women diagnosed with breast cancer can receive treatment comparable with nonpregnant women leading to a similar survival when matched for stage at diagnosis. The majority of children who were exposed to chemotherapy in utero did not demonstrate significant complications. We report the single largest cohort of women diagnosed with breast cancer during pregnancy.
Authors:
Elyce Cardonick; Rebecca Dougherty; Generosa Grana; Dzhamlaa Gilmandyar; Sadia Ghaffar; Aniqa Usmani
Related Documents :
22706886 - Safety concerns regarding binge drinking in pregnancy: a review.
15198046 - Oropharyngeal carcinoma during pregnancy: clinical and psycho-oncological aspects.
18795086 - Successful childbirth in a patient with chronic myelogenous leukemia treated with imati...
19752526 - Pregnancy outcome in maternal crigler-najjar syndrome type ii: a case report and system...
24105826 - Drugs associated with teratogenic mechanisms. part i: dispensing rates among pregnant w...
7869066 - Maternal build and pregnancy outcome.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer journal (Sudbury, Mass.)     Volume:  16     ISSN:  1540-336X     ISO Abbreviation:  Cancer J     Publication Date:    2010 Jan-Feb
Date Detail:
Created Date:  2010-02-18     Completed Date:  2010-05-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100931981     Medline TA:  Cancer J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  76-82     Citation Subset:  IM    
Affiliation:
Departments of Obstetrics and Gynecology, Cooper University Hospital, University of Medicine and Dentistry of New Jersey, Camden, NJ, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / diagnosis*,  drug therapy,  surgery
Combined Modality Therapy
Female
Follow-Up Studies
Gestational Age
Humans
Infant, Newborn
Middle Aged
Neoplasm Recurrence, Local / diagnosis*,  drug therapy,  surgery
Neoplasm Staging
Pregnancy
Pregnancy Complications, Neoplastic / diagnosis*,  drug therapy,  surgery
Pregnancy Outcome
Prospective Studies
Registries
Risk Factors
Survival Rate
Young Adult
Chemical
Reg. No./Substance:
0/Antineoplastic Agents
Comments/Corrections
Comment In:
Cancer J. 2010 Jan-Feb;16(1):68-9   [PMID:  20164694 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patien...
Next Document:  Hormone replacement therapy and messenger RNA expression of estrogen receptor coregulators after exe...